Background-Left ventricular hypertrophy (LVH) displays significant gender-based differences. 17␤-estradiol (E2) plays an important role in this process because it can attenuate pressure overload hypertrophy via 2 distinct estrogen receptors (ERs): ER␣ and ER␤. However, which ER is critically involved in the modulation of LVH is poorly understood. We therefore used ER␣-deficient (ER␣ Ϫ / Ϫ ) and ER␤-deficient (ER␤ Ϫ / Ϫ ) mice to analyze the respective ER-mediated effects. Methods and Results-Respective ER-deficient female mice were ovariectomized and were given E2 or placebo subcutaneously using 60-day release pellets. After 2 weeks, they underwent transverse aortic constriction (TAC) or sham operation. In ER␣ Ϫ / Ϫ animals, TAC led to a significant increase in ventricular mass compared with sham operation. E2 treatment reduced TAC induced cardiac hypertrophy significantly in wild-type (WT) and ER␣ Ϫ / Ϫ mice but not in ER␤ Ϫ/Ϫ mice. Biochemical analysis showed that E2 blocked the increased phosphorylation of p38 -mitogen-activated protein kinase observed in TAC-treated ER␣ Ϫ / Ϫ mice. Moreover, E2 led to an increase of ventricular atrial natriuretic factor expression in WT and ER␣ Ϫ / Ϫ mice. Conclusions-These findings demonstrate that E2, through ER␤-mediated mechanisms, protects the murine heart against LVH. (Arterioscler Thromb Vasc Biol. 2006;26:1524-1530.) 
T he increase of left ventricular mass represents a structural mechanism of compensation of the heart in response to pressure overload. The resulting left ventricular hypertrophy (LVH) is an important, independent negative predictor of cardiac morbidity and mortality. 1 LVH displays significant gender-based differences. Premenopausal women have a lower prevalence of LVH than men. 2 The Coronary Artery Risk Development In young Adults (CARDIA) study demonstrated a higher prevalence of LVH in men, even after correction for a large number of risk factors. It further demonstrated that the difference in left ventricular size begins early in life (ie, before menopause), suggesting that intrinsic factors are involved in the induction of LVH. 2 Sex hormones such as estrogen have been attributed to play an important role in the pathogenesis of cardiovascular disease. The recent clinical trials with respect to the therapeutic role of 17␤estradiol (E2) vascular disease are controversial. 3 However, the potential of E2 as a therapeutic option in the modulation of cardiac disease remains poorly understood. It has been demonstrated that estrogens are able to attenuate hypertrophic responses. 4 ,5 E2 appears to act as a cardioprotective steroid hormone. However, the underlying mechanisms of E2 protection of the myocardium are not fully understood. Myocytes and fibroblasts contain functional estrogen receptors (ERs) ER␣ and ER␤. Via these receptors, E2 modulates the activity of the mitogen-activated protein kinase (MAPK) pathways in cardiac myocytes. 6 The MAPK signaling pathways consist of a sequence of successively acting kinases that ultimately result in the dual phosphorylation and activation of effector kinases such as p38-MAPKs, c-Jun N-terminal kinases (JNKs), and extracellular signal-regulated kinases (ERKs), which subsequently phosphorylate a large array of targets, leading to altered gene expression patterns. 7 These signaling cascades play an important role in the initiation of cardiac hypertrophy and in the development of heart failure. 7-10 E2 can inhibit p38-MAPK phosphorylation and thus p38-MAPK activation. 11 Furthermore, it is known that E2 can increase the expression of the atrial natriuretic factor (ANF), which recently has been shown to possess antihypertrophic effects. 5, [11] [12] [13] Significant increases in ANF mRNA are detected in the mouse ventricle that is challenged by aortic banding. 11 However, little is known about the respective role of the distinct ERs. We recently reported the effects of E2 on the development of pressure-overload hypertrophy and the activation of signaling pathways of MAPKs. 11 Furthermore, new studies suggest that ER␤ plays an important role in cardiac disease. 14 Here, we further define the role of ERs in this process. For this goal, we used ER␣-deficient (ER␣ Ϫ / Ϫ ) and ER␤-deficient (ER␤ Ϫ / Ϫ ) mice. We found that cardioprotective effects of E2 on LVH are mediated by ER␤ and not ER␣. These effects are paralleled by an increase in the expression of ANF and a decrease in the phosphorylation of p38.
Materials and Methods
Animals ER␣ Ϫ / Ϫ transgenic mice were generated using C57BL/6 as background as described previously. 15 These mice, which have been extensively studied, do not express ER␣ protein in any tissue. [15] [16] [17] [18] ER␤ Ϫ / Ϫ mice were generated and provided by Organon (Oss, the Netherlands). For details, see the online supplement, available at http://atvb.ahajournals.org. Mice showing germline transmission were again crossed with C57BL/6 mice (F2ϩ F3 generation). Subsequently, mice from the same litters were used for breeding. Wild-type (WT) littermates from the respective genotypes were used in the study. Only female mice of Ϸ10 weeks age were incorporated into this study.
Experimental Procedures
All animals (300 WT and knockout mice) were housed under standard conditions. Animals were anesthetized with ketamine (100 mg/kg body weight [BW] IP) and xylazine (10 mg/kg BW IP) for ovariectomy, pellet placement, and transverse aortic constriction (TAC). The study was approved by the animal ethics committee of the University of Maastricht.
Estrogen Replacement
Two weeks after ovariectomy, a 60-day-release pellet containing 0.18 mg E2 or placebo was implanted subcutaneously. All pellets were purchased from Innovative Research of America. E2 serum levels were measured with a radioimmunoassay (DPC Biermann) in a subset of animals.
Surgical Procedures and Hemodynamics
Ovariectomy was performed by a standard bilateral abdominal approach. The uterus was left remaining to study the responsiveness to hormone replacement therapy. Afterward, placebo or E2containing pellets were implanted in the upper neck subcutaneously. Two weeks after the pharmacological intervention, TAC was performed, as described previously. 11 Sham-operated animals underwent an identical operation without placement of the constricting suture. Assessment of left ventricular function was performed as described previously. 19, 20 Conductance and pressure input was digitized with a Conduct-PC data acquisition system (CDLeycom BV). Average values for mean arterial pressure, heart rate, systolic and diastolic LV pressure, and left ventricular end-diastolic pressure were determined. The mortality in all treatment groups during the surgery did not differ significantly between groups. In particular, no increased mortality was found in the estrogen treatment groups and the ER␤ animal groups.
Tissue Preparation and Histology
Hearts were arrested in diastole with CdCl 2 (0.1 mol/L IV). For morphometric analysis, hearts were fixed in 10% formalin and embedded in paraffin as described previously. 21 For protein extraction, hearts were excised and washed in ice-cold PBS. All external fluid was completely removed before the organs were weighed and frozen. Transverse sections of the heart were stained with hematoxylin and eosin, sirius red, or modified Azan. The analysis of the collagen content was performed with a computerized morphometry system as described previously. 21 
Immunoblot Analysis
Total heart lysates (40 g per lane) were analyzed by standard immunoblotting procedures as described previously. 22 For details, see the online supplement.
Real-Time Polymerase Chain Reaction Analysis
Details of the real-time RT-PCR have been described previously. 23 The primer sequences used for real time PCR are: ANF 5Ј primer (5Ј-CCT GTG TAC AGT GCG GTG TC), ANF 3Ј primer (5Ј-TCC TCC AGG TGG TCT AGC A), cyclophillin 5Ј primer (5Ј-CAA ATG CTG GAC CAA ACA CAA), cyclophillin 3Ј primer (5Ј-TTC ACC TTC CCA AAG ACC ACA T). The CT measurement is defined at the fractional cycle number at which the amount of amplified target reaches a fixed threshold above background Sybr Green fluorescence. The amount of target in the cDNA sample relative to cyclophiline was calculated.
Statistical Analysis
Data are shown as meanϮSEM. Means were compared by ANOVA, followed by Bonferroni test for multiple comparisons. Differences were considered significant at PϽ0.05. 24 
Results
In our study, we divided the cardiac analysis of the animals in a total of 16 different groups, as shown in the Table. The different groups underwent either sham or TAC surgical procedures and were ovariectomized after E2 substitution. A complete phenotypic analysis of both cardiac and endocrine parameters was performed to study the receptor-mediated effects in all animal groups studied (Table) . E2 replacement led to a reconstitution of physiological E2 levels (122 pg/mL in E2-treated versus Ͻ5 pg/mL in placebo-treated). Uterus weight (UW) was measured to demonstrate the effectiveness of ovariectomy and E2 substitution in all animals. In all groups (8 conditions with TAC or sham and placebo or E2 treatment for ER␣ Ϫ / Ϫ as well as ER␤ Ϫ / Ϫ ), the UW/BW and UW/tibia length (TL) ratios showed a significant difference between placebo and E2-treated mice (Table) . In E2-treated WT and ER␤ Ϫ / Ϫ mice, the UW/BW ratios are significantly higher than that of E2-treated ER␣ Ϫ / Ϫ mice (Table) . Together, we were able to demonstrate that ovariectomy leads to uterus atrophy on the basis of E2 withdrawal, and E2 replacement restored UW. There were no significant differences in BW between the groups and no significant changes in lung weight (Table) .
In all animal groups, TAC led to a significant increase in ventricular mass 4 weeks after the intervention. E2 treatment led to a significant reduction of the increase of ventricular weight (VW) and the VW/TL ratio in WT and ER␣ Ϫ / Ϫ mice ( Figure 1 ). No differences were observed between shamoperated mice (Figure 1 ; data not shown). Also in ER␤ Ϫ / Ϫ mice and their WT littermates, TAC led to significant increase in ventricular mass 4 weeks after the intervention. In WT mice, TAC the degree of ventricular hypertrophy were significantly lower in E2-treated compared with placebotreated mice. Interestingly, E2 treatment in ER␤ Ϫ / Ϫ mice resulted in a higher level of hypertrophy compared with WT mice. Similar results were found when we used VW/BW (please see the online supplement; data not shown). No significant differences were observed among the shamoperated mice (Figure 1 ). Weight analyses are in line with morphometric analyses (please see the online supplement).
The most surprising finding was the lack of inhibition of hypertrophy in the ER␤ Ϫ / Ϫ mice. Therefore, we performed invasive hemodynamic measurements to check whether the blunted response had an effect on left ventricular function.
Hemodynamic analysis showed that developed pressure, as an indication of the quantity of afterload, was significantly increased in TAC ER␣ Ϫ / Ϫ and ER␤ Ϫ / Ϫ instrumented mice compared with sham mice (please see the online supplement). E2 treatment had no influence on the degree of pressure overload compared with placebo-treated mice (please see the online supplement). There was no significant difference . VW/TL ratios from animals with TAC or SHAM that were treated with E2 or placebo for 4 weeks after intervention. The degree of ventricular hypertrophy was significantly lower in E2-treated than placebotreated WT and ER␣ Ϫ / Ϫ mice with pressure overload. E2 treatment led to a significant reduction in the degree of hypertrophy in WT but not in ER␤ Ϫ / Ϫ mice. All values are meanϮSEM; nϭfor 7 sham and 10 for TAC per group. *PϽ0.05 for TAC vs sham; ϩPϽ0.05 for E2 vs placebo.
Effects of TAC and E2 Treatment on BW and Organ Weight
between ER␣ Ϫ / Ϫ and ER␤ Ϫ / Ϫ mice. Cardiac performance remained at normal WT level because no significant differences in cardiac output and heart rate were detected between groups (please see the online supplement). Even in the ER␤ Ϫ / Ϫ mice, no deterioration of cardiac function was observed after 4 weeks of pressure overload. Hypertrophic growth is therefore not necessary to maintain cardiac performance in the situation of pressure overload. This is not in accordance with the general consensus that hypertrophy is an obligatory compensating mechanism to withstand augmented hemodynamic stress. In this study, ventricular contraction and relaxation did not alter between genotypes nor substitution therapies after TAC. Maximal derivative of left ventricular pressure (dP/dt max ) increased and minimal derivative (dP/dt min ) decreased, although no significant differences were found between groups (Figure 2 ). The pressure volume loops showed the absence of significant differences in cardiac performance between placebo-and E2-treated ER␤ Ϫ / Ϫ (Figure 2) , except for the TAC-induced systolic pressure rises. Data in ER␣ Ϫ / Ϫ mice are comparable (data not shown). E2 had no influence on the degree of pressure overload as determined by the pressure gradient or the prestenotic pressure (data not shown).
To analyze the mechanisms involved in the observed antihypertrophic effect of E2, we investigated critical target genes involved in development and progression of cardiac hypertrophy. In previous reports, these genes have been shown to be regulated by E2. 4 Immunoblot analysis revealed that E2 blocked the increased phosphorylation of p38-MAPK in ovariectomized WT and ER␣ Ϫ / Ϫ mice with pressure overload hypertrophy, whereas it exerted no effect in sham-operated animals and ER␤ Ϫ / Ϫ mice (Figure 3 ). No differences could be observed between the study groups with regard to the phosphorylation level of ERK1/2 and JNK (data not shown).
Furthermore, TAC led to a significant increase in ANF expression in the hypertrophied ventricles of WT and ER␣ Ϫ / Ϫ mice 4 weeks after intervention compared with placebo-treated and ER␤ Ϫ / Ϫ mice (PϽϮ0.05); however, in ER␤ Ϫ / Ϫ mice, no such effect was found (Figure 3 ). No significant difference was seen between placebo-treated animals in both groups. Also, E2-treated WT mice showed a nonsignificant difference between E2-treated WT of ER␣ Ϫ / Ϫ and ER␤ Ϫ / Ϫ animals (Figure 3 ).
Discussion
ER-mediated effects in cardiovascular disease require a better understanding because of the controversial findings of previous clinical studies of hormone replacement therapy. 25 These prospective studies focused on primary and secondary prevention of ischemic heart disease. Despite these recent observations, little is known about the role of ERs in cardiac disease such as cardiac hypertrophy. A better understanding of the function of specific ERs in different tissues is important in the development and selection of new agents that could be used for treatment. Currently, the biological roles of these 2 different ER subtypes are not clear. It may be related to the selective actions of E2 in various target tissues. Also, it is known that different E2 compounds have different relative binding affinities for ER␣ versus ER␤. 26, 27 For instance, recent studies suggest that ER␤ may inhibit the stimulatory effects of ER␣ on cellular proliferation. 28 In the case of E2 signaling, cellular selectivity for one or the other ER appears to be regulated by the cellular expression pattern of the ERs and interacting coactivator and corepressor proteins. 29 The ER␣ appears to be more involved in regulation of uterine growth than the ER␤, as can be deduced from both the uterine wet weight and the uterine dry weight in ER␣ Ϫ / Ϫ mice (Table) . This is in line with previous studies regarding the importance of ER␣ for the uterine response. 15, 30 On the other hand, ER␤, as we proved in this study, mediates the attenuation of pressure overload hypertrophy by E2. Because of the overall number required to study all treatment groups to reach statistical significance, we focused on the well-established time point of 4 weeks after TAC.
Whereas in ER␣ Ϫ / Ϫ mice, VW is significantly reduced (comparable to WT) after addition of E2, no such effect is seen in ER␤ Ϫ / Ϫ . Moreover, in ER␤ Ϫ / Ϫ mice, there was a nonsignificant tendency toward hypertrophy when E2 was present and a tendency toward decreased hypertrophy in the absence of E2. Together, our study supports the hypothesis that E2 has direct, modulating effects on cardiac myocytes and the heart. Similar results were also obtained by Skavdahl et al 31 in a model of hypertrophy that evaluated gender-based differences and added the important observation that gender determines the hypertrophic phenotype. Furthermore, Pelzer et al 32 demonstrated that in ER␤ Ϫ / Ϫ animals of a different genetic background than the animals used in our study, an increase of mortality was shown. The findings of Pelzer et al underline the importance of ER␤ for the cardiovascular system, in particular for cardiac dimensions and function. Although ER␤ appears to be of major importance in the ER-dependent responses studied in this investigation, ER␤ also plays a role in other physiological contexts such as the development of cardiac arrhythmias after myocardial infarction. 14 There, ER␤ was shown to play an important role in ventricular repolarization after myocardial infarction and the regulation of the potassium channel expression. Furthermore, it was demonstrated, using the same animal model, that ER␤ is necessary for normal morphology in several regions of the central nervous system. 33 Studies on these animals also indicate that ER␤ has an antiproliferative effect in the immature uterus and in the prostate, at least partially by balancing the proliferative activity of ER␣. 34 To further elucidate the mechanisms involved in the antihypertrophic effects of E2, it will be necessary to identify the additional signaling molecules involved in these protective effects, their time course of activation, and the cross-talk between them.
In a previous study, we showed that no differences occur in the expression levels of ERK1/2, JNK, angiotensin II type 1 receptor, or angiotensin-converting enzyme. 11 To further elucidate possible mechanisms involved, we studied the activation of MAPK and ANF. These have been shown to play important roles in the development and progression of cardiac hypertrophy. 9 It has been reported that the activation of p38-MAPK is important for the hypertrophic response and maintains the hypertrophic response over a longer period of time. 35 E2 can inhibit p38-MAPK phosphorylation and thus p38-MAPK activation. Our results are in line with van Eickels et al, 11 who demonstrated that inhibition of p38-MAPK phosphorylation by E2 treatment may represent one of the mechanisms by which E2 exerts its antihypertrophic effect in the TAC model of pressure overload.
Antihypertrophic properties of ANF were shown in several studies. 5, 11, 12, 35 In line with these results, E2 led to a significant increase in ANF expression in the ventricles of WT and ER Ϫ / Ϫ animals compared with placebo-treated WT and E2-treated ER␤ Ϫ / Ϫ mice with pressure overload. ANF expression was noticed early after hypertrophic stimulation; it occurs after 6 to 12 hours. 36 These findings confirm that ANF is part of another pathway by which E2 exerts its antihypertrophic effects. Together, we provide new evidence for the role of cardiac ERs in the development of LVH.
However, the role of E2 in the development of LVH is poorly understood. Many observational studies suggest that estrogen replacement therapy has cardioprotective effects in postmenopausal women. 37, 38 However, recent clinical trials have failed to show a cardiovascular benefit of estrogen replacement therapy in women with established coronary artery disease. 39 Our results show that the antihypertrophic effects of E2 are receptor specific. This may stimulate research for ligands that only bind ER␤. Such a development may circumvent the negative effects reported in the Heart and Estrogen Replacement Study (HERS) and Women Health Initiative Study (WHI) studies and provide for a precisely targeted antihypertrophic approach.
Conclusion
Our results showed that ER␤ plays a role in the control of LVH. Protective effects of E2 in murine heart via ER␤ appear to increase expression of ANF and decreased p38 phosphorylation. The fact that cardiovascular action of E2 relies largely on ER␤ provides opportunities to develop more specific interventional strategies to treat hypertrophy, avoiding side effects.
